A transitional B-cell cytokine biomarker for risk stratifying renal transplant patients with borderline rejection.
A transitional B-cell cytokine biomarker for risk stratifying renal transplant patients with borderline rejection.
复制标题
一种过渡 B 细胞细胞因子生物标志物，用于对边缘排斥的肾移植患者进行风险分层。
DOI：
10.1016/j.kint.2022.12.020
复制
发表时间：
2023
影响因子：
19.6
通讯作者：
Chong,AnitaS
中科院分区：
文献类型：
--
作者：
Basu,Sumoyee;Dorling,Anthony;Chong,AnitaS
交界性同种异体移植排斥反应可促进部分(但不是全部)患者的急性排斥反应和移植物丢失。在这一期中，Cherukuriet等人使用了一种基于外周血过渡性T1 B细胞产生白介素10和肿瘤坏死因子-α的新检测方法，该方法可以识别预后不良的高风险患者。过渡性T1 B细胞可能调节同种异体反应性的潜在机制需要探索，但在适当的验证之后，该生物标记物可能会使需要早期干预的患者分层。
Borderline allograft rejection can promote acute rejection and graft loss in some, but not all, patients. In this issue, Cherukuriet al.use a novel test based on peripheral blood transitional T1 B cells producing interleukin-10 and tumor necrosis factor-α, which identifies patients at high risk for poor outcomes. The potential mechanisms by which transitional T1 B cells might modulate alloreactivity need exploration, but following appropriate validation, this biomarker could risk stratify patients in need of early intervention.